Please provide your email address to receive an email when new articles are posted on . Teprotumumab reduces proptosis by 2 mm or more for most adults with long-standing thyroid eye disease and low ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Pretreatment evaluation of fat-to-muscle ratio in thyroid eye disease will allow for the best ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Findings from THRIVE showed treatment with veligrotug led to statistically significant improvements in the signs and symptoms of TED. Topline data were announced from a phase 3 study evaluating ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial (OPTIC-J) in Japan evaluating teprotumumab for the ...

Study findings presented at the American Society of Ophthalmic Plastic & Reconstructive Surgery's 2021 Fall Scientific Symposium detail the benefits of teprotumumab for thyroid eye disease. New ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teprotumumab (Tepezza, Amgen) as the first treatment to be licensed in the UK for adults with moderate-to-severe thyroid eye ...

Viridian Therapeutics (VRDN) appears to be ending on a high note in 2024, because it just reported positive results from its phase 3 THRIVE-2 study using its anti-IGF-1R drug veligrotug [VRDN-001] to ...

- Priority Review designation is granted to applications for drugs that, if approved, would be a significant improvement in the safety or effectiveness of treating a serious condition - - Veligrotug ...